Inhibikase Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Inhibikase Therapeutics, Inc. (IKT) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$108.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-11
- Inhibikase Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$89.65M, a 628.86% decline year-over-year.
- Inhibikase Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $16.95M.
- Inhibikase Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$6.81M.
- Inhibikase Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$3.23M.
- Inhibikase Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $82.73M, a 74.81% increase from fiscal 2024.
- Inhibikase Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $47.33M, a 2294.25% increase from fiscal 2023.
- Inhibikase Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $1.98M.
- Inhibikase Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$33.56M, a 225.25% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$108.01M 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | -$89.65M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $82.73M 10-K · filed 2026-03-26 | |||
| 2025-09-30 | -$18.22M 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $21.25M 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | $16.95M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $47.33M 10-K · filed 2026-03-26 | |||
| 2024-09-30 | -$8.25M 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | -$6.08M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$6.81M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $1.98M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $7.67M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$5.28M 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$3.23M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$33.56M 10-K · filed 2024-03-27 | |||
| 2022-09-30 | -$34.97M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$8.54M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$4.14M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $26.80M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $30.89M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $32.88M 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | -$4.34M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $13.94M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | -$2.29K 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$10.67K 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | -$5.31K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |